News & Updates
Filter by Specialty:
Investigational imaging agent holds promise for diagnosing renal cancer
In the pivotal phase III ZIRCON study, PET/CT imaging with 89Zr-DFO-girentuximab, an investigational imaging agent, demonstrated potential in the noninvasive identification of clear-cell renal cell carcinoma (ccRCC) in patients with indeterminate renal masses (IDRM).
Investigational imaging agent holds promise for diagnosing renal cancer
17 Apr 2023
Add-on immunotherapy improves PFS in 1L advanced or recurrent endometrial cancer
Adding dostarlimab or pembrolizumab to standard first-line (1L) chemotherapy significantly improves progression-free survival (PFS) in patients with advanced or recurrent endometrial cancer, two phase III trials have shown.
Add-on immunotherapy improves PFS in 1L advanced or recurrent endometrial cancer
17 Apr 2023
Idecabtagene vicleucel boosts PFS and responses vs standard regimens in triple class–exposed R/R MM
Idecabtagene vicleucel (ide-cel), a B-cell maturation antigen–directed chimeric antigen receptor (CAR) T-cell therapy, improves progression-free survival (PFS) and responses vs standard regimens in patients with triple class–exposed relapsed and refractory multiple myeloma (R/R MM), the phase III KarMMa-3 trial has shown.
Idecabtagene vicleucel boosts PFS and responses vs standard regimens in triple class–exposed R/R MM
17 Apr 2023
Endoscopic submucosal dissection safer, more cost-effective than transanal endoscopic microsurgery
In patients with early rectal cancer (ERC), endoscopic submucosal dissection (ESD) appears safer and is associated with shorter hospital stay than transanal endoscopic microsurgery (TEM), results of a recent study have shown.
Endoscopic submucosal dissection safer, more cost-effective than transanal endoscopic microsurgery
15 Apr 2023
HF drug provides 24-hour BP-lowering effect in Asians with hypertension
The angiotensin receptor neprilysin inhibitor sacubitril/valsartan, used for heart failure, appears to have potent effects on 24‐hour blood pressure (BP) in Japanese patients with mild‐to‐moderate hypertension and in the subgroup of those with nondipping BP pattern, as shown in a study.